Cemiplimab vs Pembrolizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03088540 · Phase 3 · completed

This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.

Next expected readout: December 2026 · NCT06623656 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)

Result source: NCT03088540

Pembrolizumab

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02142738 · Phase 3 · completed

The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).

Next expected readout: November 2026 · NCT06545331 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)

Result source: NCT02142738

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemiplimabPembrolizumab
PFS, median6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
OS, median21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
ORR43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
Duration of response, median16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results

PFS, median

Cemiplimab
6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
Pembrolizumab
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results

OS, median

Cemiplimab
21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
Pembrolizumab
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results

ORR

Cemiplimab
43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
Pembrolizumab
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474

Duration of response, median

Cemiplimab
16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
Pembrolizumab
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cemiplimab: 4 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabPembrolizumab
Rows use multiple source trials
Dropout rate
79%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
90.7%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
90.1%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumabb
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
54%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
58.8%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
n/a: no completion milestone
NCT02775435 · Phase 3 · combination
n/a: no completion milestone
NCT02220894 · Phase 3
n/a: no completion milestone
NCT02504372 · Phase 3
89.3%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
33%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
0%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02864394 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03850444 · Phase 3 · registry result, not featured evidence
2.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
90.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
80.7%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
89.2%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
94.4%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02955758 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
3.2%
NCT02733159 · Phase 2 · registry result, not featured evidence
87.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
86.4%
NCT03087760 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.3%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
0%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
0.3%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
8.4%Pembrolizumabb
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
4.9%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
6.7%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
11.5%
NCT02775435 · Phase 3 · combination
19.9%
NCT02220894 · Phase 3
—
NCT02504372 · Phase 3
—200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
—Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
—
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
—
NCT02864394 · Phase 3 · registry result, not featured evidence
12.5%
NCT03850444 · Phase 3 · registry result, not featured evidence
—
NCT03634241 · Phase 2 · registry result, not featured evidence
—Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—
NCT02955758 · Phase 2 · registry result, not featured evidence
—Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02733159 · Phase 2 · registry result, not featured evidence
12.3%
NCT03004183 · Phase 2 · registry result, not featured evidence
11.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
—
NCT03087760 · Phase 2 · registry result, not featured evidence
Serious AEs
36.8%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
27.1%Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
35.2%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
30.4%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—Pembrolizumabb
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
51.3%Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
16.7%Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
38.8%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
36.6%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
57.5%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
22.2%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
46%
NCT02775435 · Phase 3 · combination
41%
NCT02220894 · Phase 3
24.5%
NCT02504372 · Phase 3
20.7%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
35%Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
37.7%Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7.7%Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
23.4%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
50%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
100%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
54.7%Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
35.1%
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
53.8%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
36%
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
36.2%
NCT02864394 · Phase 3 · registry result, not featured evidence
32.8%
NCT03850444 · Phase 3 · registry result, not featured evidence
7.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
9.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
20%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60.8%800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
46.7%200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
52.5%Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
47.6%Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
37.8%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
47.4%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
54.1%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
25%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
36%
NCT02955758 · Phase 2 · registry result, not featured evidence
58.9%Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.1%Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
85%
NCT02733159 · Phase 2 · registry result, not featured evidence
51.8%
NCT03004183 · Phase 2 · registry result, not featured evidence
40.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
45.5%
NCT03087760 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
anaemia 19.7%
decreased appetite 13.8%
fatigue 13.5%
NCT03088540 · Phase 3
show 10 more results
anaemia 31.8%
alopecia 22.4%
diarrhoea 18.8%
NCT03088540 · Phase 3 · combination
anaemia 48.1% (placebo 39.9%)
neutropenia 28.7% (placebo 12.4%)
alopecia 27.8% (placebo 43.8%)
NCT03409614 · Phase 3 · combination
anaemia 33.9% (placebo 39.9%)
nausea 28.4% (placebo 16.3%)
fatigue 21.1% (placebo 8.5%)
NCT03409614 · Phase 3 · combination
anaemia 44.2% (placebo 39.9%)
alopecia 37.5% (placebo 43.8%)
nausea 25.3% (placebo 16.3%)
NCT03409614 · Phase 3 · combination
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
b
diarrhoea 26.6%
dyspnoea 26.6%
fatigue 24%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 42 more results
upper respiratory tract infection 33.3%
constipation 16.7%
decreased appetite 16.7%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
10 mg/kg
fatigue 25.7%
decreased appetite 23.3%
dyspnoea 23%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
2 mg/kg
decreased appetite 30.7%
fatigue 30.1%
nausea 25.7%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
nausea 57.3% (placebo 51%)
anaemia 45.9% (placebo 45%)
fatigue 42.7% (placebo 39.6%)
NCT02578680 · Phase 3 · combination
abdominal pain 22.2% (placebo 6.4%)
cough 22.2% (placebo 30.7%)
diarrhoea 22.2% (placebo 20.3%)
NCT02578680 · Phase 3 · combination
anaemia 53.2% (placebo 49.6%)
alopecia 46% (placebo 37.5%)
nausea 36.3% (placebo 32.1%)
NCT02775435 · Phase 3 · combination
decreased appetite 17%
cough 16.8%
dyspnoea 16.5%
NCT02220894 · Phase 3
weight increased 22.8% (placebo 28.9%)
pruritus 21.6% (placebo 12.7%)
hypothyroidism 20.7% (placebo 4.6%)
NCT02504372 · Phase 3
200 mg IV Q3W
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
anaemia 36.2%
nausea 24%
fatigue 17.2%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 37.7%
nausea 19%
aspartate aminotransferase increased 16.6%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 14.3%
covid-19 14.3%
headache 14.3%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 15.4%
cough 15.4%
productive cough 15.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 38.4%
nausea 30.9%
neutropenia 23.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anemia 75%
cough 75%
abdominal pain 50%
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03867175 · Phase 3 · registry result, not featured evidence
hypertension 41.4%
diarrhoea 40.9%
hypothyroidism 35.4%
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
anaemia 40.4% (placebo 44.7%)
nausea 39.2% (placebo 43.5%)
neutrophil count decreased 36.7% (placebo 45.9%)
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
alopecia 78.5%
white blood cell count decreased 78.5%
neutrophil count decreased 76.9%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
nausea 72% (placebo 53.3%)
constipation 64% (placebo 73.3%)
decreased appetite 56% (placebo 60%)
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
anaemia 33.3%
aspartate aminotransferase increased 21.6%
cough 21.6%
NCT02864394 · Phase 3 · registry result, not featured evidence
anaemia 30.5%
cough 23.4%
pyrexia 22.7%
NCT03850444 · Phase 3 · registry result, not featured evidence
fatigue 45%
investigations 25%
alanine aminotransferase increased 20%
NCT03634241 · Phase 2 · registry result, not featured evidence
anaemia 42.9%
diarrhoea 33.3%
fatigue 28.6%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
asthenia 40%
blood creatinine increased 40%
blood urea increased 40%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
800 mg
diarrhoea 29.4%
fatigue 21.6%
alanine aminotransferase increased 19.6%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
200 mg
pyrexia 23.3%
constipation 20%
decreased appetite 20%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
hypertension 52.5%
diarrhoea 45%
hypothyroidism 36.3%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
pruritus 29.3%
cough 22%
fatigue 20.7%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
fatigue 29.7%
pruritus 29.7%
nausea 24.3%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
asthenia 34.2%
dyspnoea 34.2%
cough 29.8%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
asthenia 21.6%
anaemia 18.9%
cough 18.9%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 36.1%
dyspnoea 36.1%
cough 30.6%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
nausea 24%
decreased appetite 20%
worsening abdominal pain 20%
NCT02955758 · Phase 2 · registry result, not featured evidence
anaemia 39.3%
fatigue 34.8%
alopecia 31.3%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
nausea 52%
asthenia 40.2%
anaemia 32.4%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
fatigue 60%
dyspnea 48.3%
cough 35%
NCT02733159 · Phase 2 · registry result, not featured evidence
fatigue 21.4%
nausea 12.5%
back pain 10.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
fatigue 56.5%
hypoalbuminemia 44.9%
hyponatremia 39.1%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
esophagitis 36.4%
fatigue 36.4%
hypothyroidism 22.7%
NCT03087760 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 42 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cemiplimab

EORTC QLQ-C30 GHS 4.92 vs 0.45 Chemotherapy score @ 3wk
absolute change · score
Cycle 2, Day 1 (C2D1)
NCT03088540 · Phase 3
show 2 more results
2.13 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
1.58 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 7.23 vs 1.25 Chemotherapy score @ 6wk
absolute change · score
C3D1
NCT03088540 · Phase 3
show 3 more results
4.65 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
2.75 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
0.96 vs 2.8 placebo score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.13 vs 2.43 Chemotherapy score @ 9wk
absolute change · score
C4D1
NCT03088540 · Phase 3
show 3 more results
6.22 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
3 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
1.92 vs 4.09 placebo score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.27 vs 1.88 Chemotherapy score @ 12wk
absolute change · score
C5D1
NCT03088540 · Phase 3
show 3 more results
3.31 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
4.72 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
3.35 vs 2.28 placebo score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 9.64 vs 3 Chemotherapy score @ 15wk
absolute change · score
C6D1
NCT03088540 · Phase 3
show 3 more results
5.63 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.38 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.42 vs 2.89 placebo score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.19 vs 2.55 Chemotherapy score @ 24wk
absolute change · score
C9D1
NCT03088540 · Phase 3
show 3 more results
6.87 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
1.8 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
3.65 vs 2.02 placebo score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 11.11 vs -4.17 Chemotherapy score @ 33wk
absolute change · score
C12D1
NCT03088540 · Phase 3
show 3 more results
4.44 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
9.15 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
2.37 vs 3.54 placebo score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.88 vs 5.36 Chemotherapy score @ 42wk
absolute change · score
C15D1
NCT03088540 · Phase 3
show 3 more results
7.35 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
9.4 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
6.23 vs 6.61 placebo score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.1 vs -3.03 Chemotherapy score @ 51wk
absolute change · score
C18D1
NCT03088540 · Phase 3
show 3 more results
6.73 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
14.44 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
5.28 vs 10.09 placebo score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 13.42 vs -1.19 Chemotherapy score @ 60wk
absolute change · score
C21D1
NCT03088540 · Phase 3
show 3 more results
11.36 vs 0 Chemotherapy score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
15.71 vs 0 Chemotherapy score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
6.07 vs 18.59 placebo score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.76 vs 1.19 Chemotherapy score @ 69wk
absolute change · score
C24D1
NCT03088540 · Phase 3
show 3 more results
8.33 vs -11.11 Chemotherapy score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
14.29 vs -11.11 Chemotherapy score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
5.05 vs 10.83 placebo score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 12.5 vs -3.33 Chemotherapy score @ 78wk
absolute change · score
C27D1
NCT03088540 · Phase 3
show 3 more results
8.89 vs -22.22 Chemotherapy score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination
19.05 vs -22.22 Chemotherapy score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination
5.27 vs 8.33 placebo score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination

+ 36 further endpoints in the CSV export.

Pembrolizumab

PFS Rate at 6 62.1% (n=154) vs 50.3% (n=151) SOC Chemotherapy @ 24wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
OS Rate at 12 70.3% (n=154) vs 54.8% (n=151) SOC Chemotherapy @ 48wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.7 vs 8.5 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
10.4 vs 8.5 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
PFS 4 vs 4 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
3.9 vs 4 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.5% (n=346) vs 9.3% (n=343) Docetaxel10 mg/kg
responder rate · % of participants
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18% (n=344) vs 9.3% (n=343) Docetaxel2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response NA vs 6.23 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
NA vs 6.23 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Disease-free Survival 53.8 vs 43 placebo months
time to event · months
NCT02504372 · Phase 3
show 3 more results
67 vs 47.6 placebo months
NCT02504372 · Phase 3
58.7 vs 42.8 placebo months
NCT02504372 · Phase 3
53.6 vs 42 placebo months @ 295wk
NCT02504372 · Phase 3
PFS 7.1 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
8.3 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7 months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
2.6 months
NCT02955758 · Phase 2 · registry result, not featured evidence
29 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.3 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
4.39 months
NCT02733159 · Phase 2 · registry result, not featured evidence
Overall Survival 20.7 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
23 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03634241 · Phase 2 · registry result, not featured evidence
22.3 months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
13.3 months
NCT02955758 · Phase 2 · registry result, not featured evidence
35.6 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
56.7 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
9.8 months
NCT02733159 · Phase 2 · registry result, not featured evidence
EORTC QLQ-C30 GHS -5.34 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-3.44 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Time to Deterioration Global Health Status 19.81 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
17.28 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 -1.98 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
-1.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.47 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination

+ 44 further endpoints in the CSV export.

Melanoma

Shared mechanism: PD-1 · full Melanoma pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Phase 3 in Melanomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT05608291 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Melanomamonoclonal antibody
Partial signal

NCT01866319 · Phase 3 · completed

The trial randomized 834 participants to two pembrolizumab schedules or active-control ipilimumab, with progression assessed by blinded independent radiology review and statistically significant improvements in progression-free survival and overall survival for both pembrolizumab schedules versus ipilimumab. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the objective clinical endpoints and favorable results.

Next expected readout: December 2026 · NCT02644369 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Melanoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Cemiplimab: 3 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabPembrolizumab
Dropout rate
0%30 mg/kga
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
89.3%200 mg IV Q3Wa
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
0%30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
0%27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
0%18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
57.1%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
92.3%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
92.5%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
91.6%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
93.2%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
100%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
100%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
89%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
90.2%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
100%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
100%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
100%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—30 mg/kga
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—200 mg IV Q3Wa
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
—30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
12%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
15.3%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10.3%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
16.9%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
16.7%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
66.7%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
9.1%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
11.5%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
33.3%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Serious AEs
33.3%30 mg/kga
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20.7%200 mg IV Q3Wa
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
22.2%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
57.1%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
55.6%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
43.4%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45.3%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
36.8%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
20%Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
33.3%30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
41.7%27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
14.3%18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
14.3%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
43.9%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
41.2%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
42.6%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
41.5%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
30%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
33.3%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
42.6%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
55.7%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
0%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
33.3%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
30 mg/kga
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
200 mg IV Q3Wa
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
show 56 more results
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
5 mg weekly
fatigue 66.7%
decreased appetite 55.6%
cough 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 85.7%
cough 42.9%
hypophosphataemia 42.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 77.8%
musculoskeletal and connective tissue disorders 55.6%
cough 38.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 47.4%
musculoskeletal and connective tissue disorders 44.7%
decreased appetite 35.5%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
nausea 56.6%
fatigue 54.7%
musculoskeletal and connective tissue disorders 45.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 57.9%
musculoskeletal and connective tissue disorders 44.7%
blood alkaline phosphatase increased 36.8%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
3 mg weekly
decreased appetite 50%
cough 33.3%
diarrhoea 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
dyspnea 90%
fatigue 90%
pain 70%
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100%
cough 80%
pain 60%
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
30 Gy over 5 fractions
headache 33.3%
agitation 16.7%
dermatitis, other 16.7%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
27 Gy over 3 fractions
symptomatic radionecrosis 16.7%
constipation 8.3%
dermatitis, other 8.3%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
18-21 Gy in one fraction
symptomatic radionecrosis 14.3%
agitation 0%
constipation 0%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
20 mg/kg
hypertension 28.6%
anemia 14.3%
arthralgia 14.3%
NCT03236935 · Phase 1 · registry result, not featured evidence
10 mg/kg Q2W
fatigue 58.9%
diarrhoea 38.9%
nausea 38.3%
NCT01295827 · Phase 1 · registry result, not featured evidence
10 mg/kg Q3W
fatigue 52.1%
diarrhoea 35.5%
nausea 34.5%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10 mg/kg Q2W
fatigue 38.6%
decreased appetite 27.2%
dyspnoea 25.7%
NCT01295827 · Phase 1 · registry result, not featured evidence
10 mg/kg Q3W
fatigue 42.5%
decreased appetite 30.7%
cough 30%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10 mg/kg Q2W
fatigue 50%
decreased appetite 30%
constipation 20%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3 mg/kg Q2W
back pain 66.7%
nausea 66.7%
breast pain 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence
2 mg/kg Q3W
fatigue 47.5%
nausea 34.6%
diarrhoea 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q3W
fatigue 27.9%
diarrhoea 19.7%
constipation 16.4%
NCT01295827 · Phase 1 · registry result, not featured evidence
1 mg/kg Q2W
pruritus 75%
abdominal pain upper 25%
anaemia 25%
NCT01295827 · Phase 1 · registry result, not featured evidence
bradycardia 25%
diarrhoea 25%
fatigue 25%
NCT01295827 · Phase 1 · registry result, not featured evidence
diarrhoea 66.7%
fatigue 66.7%
pruritus 66.7%
NCT01295827 · Phase 1 · registry result, not featured evidence
decreased appetite 66.7%
fatigue 50%
depression 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

Brain Metastasis 54.1% (n=37)
responder rate · % of participants
No placebo or comparator arm
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
NCT02681549 · Phase 2 · registry result, not featured evidence
Intracranial ORR 54.1% (n=37)
responder rate · % of participants
No placebo or comparator arm
Intracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
Intracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
Extracranial 56.3% (n=37)
responder rate · % of participants
No placebo or comparator arm
Extracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
Extracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
PFS 14.4 months
time to event · months
No placebo or comparator arm
Median overall PFS
NCT02681549 · Phase 2 · registry result, not featured evidence · converted to months from 1.2 years as posted
show 1 more result
NA months
Median overall PFS
NCT02681549 · Phase 2 · registry result, not featured evidence
ORR 7% (n=14)280 mg PO BID
responder rate · % of participants
No placebo or comparator arm
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 16 more results
29.4% (n=313)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
36.7% (n=180)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
21.6% (n=287)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
19.3% (n=202)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
39.9% (n=313)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
45.6% (n=180)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
28.9% (n=287)10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
22.3% (n=202)10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
22.2% (n=18)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.2% (n=76)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
18.9% (n=53)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5.4% (n=37)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=162)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
19.7% (n=61)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
35.2% (n=162)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
23% (n=61)2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
Clinical Benefit 33.3% (n=18) @ 24wk5 mg weekly
responder rate · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
35.8% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
8.1% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=18) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.7% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
PFS 6mo 16.7% (n=18) @ 24wk5 mg weekly
event count · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
show 7 more results
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
37.7% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
8.1% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
16.7% (n=18) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
32.1% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
5.4% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
PFS 3.7 months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 19 more results
5.6 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
6.6 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
9.6 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
3.7 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3.4 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
4.4 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
5.6 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.4 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.69 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.96 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.9 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
8.2 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3.3 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
4.3 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
Overall Survival 22.5 months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 12 more results
26.8 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
13.1 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
13.4 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
25.2 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.73 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
12.52 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.79 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
23.1 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
8.9 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
32.8 months27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
12.2 months18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
Duration of Response NA months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 18 more results
NA months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
20.7 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
15.61 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
7.33 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
NA months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.14 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
Time to Response 4.3 months5 mg weekly
time to event · months
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 6 more results
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.95 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.17 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.29 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.95 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
Complete 0% (n=10) @ 52wk
responder rate · % of participants
No placebo or comparator arm
Complete response (CR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
0% (n=5) @ 52wk*
Complete response (CR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Pembrolizumab's landscape